Dementia Clinical Trial
— VR&ROfficial title:
VR&R: Providing Respite to Caregivers by Managing BPSDs and Improving QoL in People With Dementia Using Immersive VR-Therapy
The goal of this interventional trial is to learn about how immersive Virtual Reality (VR) therapy can be used at home by individuals with dementia, with assistance from their informal (e.g., friend/family) caregivers. The main question it aims to answer are: 1. Can caregivers receive quality respite time by using VR-therapy at home with their loved ones with dementia? Does this intervention reduce feelings of burden and improve well-being for caregivers? 2. Does VR-therapy help to manage behavioural and psychological symptoms (e.g., mood, apathy, agitation) and improve quality of life for individuals with dementia? 3. What types of VR "medium" (passive, interactive, or co-operative) are most effective for achieving the above objectives? Participant pairs will be asked to: - Take part in an initial at-home VR technology training session and complete a series of brief questionnaires (e.g., health history/technology use, well-being/quality of life, symptoms of dementia) - Use "VR&R" (VR Rest & Relaxation Therapy) for a period of 3 weeks (30 minute sessions, desired frequency), and answer a brief set of questions after each VR&R session - Provide feedback on the VR&R intervention in semi-structured interview with the researcher and answer additional questionnaires at a 1-week follow-up During VR&R sessions, participants with dementia will have the opportunity to choose to watch (1) immersive 360-degree videos (e.g., of a live performance, or beach), (2) play a simple game (e.g., using a hand controller to water plants), or (3) experience VR together with a researcher, who will join the session remotely. Caregivers will be asked to assist their loved one with dementia to use VR&R by helping to put on the VR headset, selecting a VR experience through a user-friendly web-based application, and remaining nearby to supervise and provide assistance as needed. During VR&R sessions, caregivers may use this time to take a personal break or complete short tasks (e.g., make a cup of coffee, have an uninterrupted phone call).
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | December 1, 2025 |
Est. primary completion date | February 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: People with dementia - Individuals who are 65 years of age or older - Individuals living at home with a family caregiver - Individuals diagnosed with dementia Exclusion Criteria: - Individuals with open wounds on face (sutured lacerations exempted) - Individuals with a history of seizures or epilepsy - Individuals with a pacemaker - Individuals with head trauma or stroke leading to their current admission - Individuals with cervical conditions or injuries that would make it unsafe for them to use the VR headset - Individuals who identify as being legally blind - Individuals with alcohol related dementia/ Korsakoff syndrome. - Individuals who have a Public Guardian and Trustee (PGT) as Substitute Decision Maker (SDM) - Individuals who cannot speak and understand English Caregiver inclusion criteria: - Individuals who identify as a primary caregiver for the PwD - Individuals who have access to the internet through a device (computer, tablet, or mobile phone) that can be used during the study Caregiver exclusion criteria: - Individuals who cannot speak and understand English - Individuals who are cognitively unable to provide informed consent for themselves - Identify as legally blind |
Country | Name | City | State |
---|---|---|---|
Canada | Acclaim Health | Oakville | Ontario |
Canada | Alzheimer's Society Toronto | Toronto | Ontario |
Canada | Chester Village | Toronto | Ontario |
Canada | Circle of Care | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto | Centre for Aging and Brain Health Innovation, Ontario AHSC AFP Innovation Fund |
Canada,
Anderson-Hanley C, Arciero PJ, Brickman AM, Nimon JP, Okuma N, Westen SC, Merz ME, Pence BD, Woods JA, Kramer AF, Zimmerman EA. Exergaming and older adult cognition: a cluster randomized clinical trial. Am J Prev Med. 2012 Feb;42(2):109-19. doi: 10.1016/j.amepre.2011.10.016. — View Citation
Appel L, Ali S, Narag T, Mozeson K, Pasat Z, Orchanian-Cheff A, Campos JL. Virtual reality to promote wellbeing in persons with dementia: A scoping review. J Rehabil Assist Technol Eng. 2021 Dec 21;8:20556683211053952. doi: 10.1177/20556683211053952. eCollection 2021 Jan-Dec. — View Citation
Appel L, Appel E, Bogler O, Wiseman M, Cohen L, Ein N, Abrams HB, Campos JL. Older Adults With Cognitive and/or Physical Impairments Can Benefit From Immersive Virtual Reality Experiences: A Feasibility Study. Front Med (Lausanne). 2020 Jan 15;6:329. doi: 10.3389/fmed.2019.00329. eCollection 2019. — View Citation
Appel L, Kisonas E, Appel E, Klein J, Bartlett D, Rosenberg J, Smith C. Introducing virtual reality therapy for inpatients with dementia admitted to an acute care hospital: learnings from a pilot to pave the way to a randomized controlled trial. Pilot Feasibility Stud. 2020 Oct 31;6(1):166. doi: 10.1186/s40814-020-00708-9. — View Citation
Appel L, Kisonas E, Appel E, Klein J, Bartlett D, Rosenberg J, Smith CN. Administering Virtual Reality Therapy to Manage Behavioral and Psychological Symptoms in Patients With Dementia Admitted to an Acute Care Hospital: Results of a Pilot Study. JMIR Form Res. 2021 Feb 3;5(2):e22406. doi: 10.2196/22406. — View Citation
Baker JR, Webster L, Lynn N, Rogers J, Belcher J. Intergenerational Programs May Be Especially Engaging for Aged Care Residents With Cognitive Impairment: Findings From the Avondale Intergenerational Design Challenge. Am J Alzheimers Dis Other Demen. 2017 Jun;32(4):213-221. doi: 10.1177/1533317517703477. — View Citation
D'Cunha NM, Nguyen D, Naumovski N, McKune AJ, Kellett J, Georgousopoulou EN, Frost J, Isbel S. A Mini-Review of Virtual Reality-Based Interventions to Promote Well-Being for People Living with Dementia and Mild Cognitive Impairment. Gerontology. 2019;65(4):430-440. doi: 10.1159/000500040. Epub 2019 May 20. — View Citation
Dermody G, Whitehead L, Wilson G, Glass C. The Role of Virtual Reality in Improving Health Outcomes for Community-Dwelling Older Adults: Systematic Review. J Med Internet Res. 2020 Jun 1;22(6):e17331. doi: 10.2196/17331. — View Citation
Huygelier H, Schraepen B, van Ee R, Vanden Abeele V, Gillebert CR. Acceptance of immersive head-mounted virtual reality in older adults. Sci Rep. 2019 Mar 14;9(1):4519. doi: 10.1038/s41598-019-41200-6. — View Citation
Munoz J, Mehrabi S, Li Y, Basharat A, Middleton LE, Cao S, Barnett-Cowan M, Boger J. Immersive Virtual Reality Exergames for Persons Living With Dementia: User-Centered Design Study as a Multistakeholder Team During the COVID-19 Pandemic. JMIR Serious Games. 2022 Jan 19;10(1):e29987. doi: 10.2196/29987. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Usability/Preference: System Usability Scale (SUS) | The System Usability Scale (SUS) will be completed by the caregiver to evaluate device usability/ease-of-use of the VR intervention (head-mounted device and VR&R application) used during the study. The SUS is a 10-item questionnaire employing 5-point Likert scales. Calculated scores range from 0-100. Higher scores indicate better system usability. | 4 Weeks | |
Other | Usability/Preference: Semi-Structured Interviews | Both participants will take part in a semi-structured interview post-intervention. The interview will include open-ended questions to explore the acceptability and usability the 3 different VR-mediums, including suggestions for improvement. | 4 Weeks | |
Other | PwD Preferences/Reactions to VR | ObsRVR Tool: During the initial home training (pre-intervention), the researcher will score the participant's reactions to each of the 3 VR mediums using the ObsRVR tool. This tool was specifically designed to capture the reactions of individuals with dementia while using VR and includes quantitative and qualitative ratings of positive reactions (engagement, enjoyment, relaxation), negative reactions (anxiety/apprehension, sadness, aggression) and reminiscence. | Baseline | |
Other | PwD Simulator Sickness | During the initial home training (pre-intervention), the researcher will observe the participant's reactions to each of the 3 VR mediums. After each medium, the researcher will administer a modified version of the MIsery SCale (MISC), a self-report measure of motion sickness (scale of 0-10 where 0 = "No Problems" and 10 = "Vomiting"). Participants who score 4 or more (i.e., "rather" dizzy/sweating/salivating) on the scale for at least two out of three of the VR mediums will be withdrawn from the study. | Baseline | |
Other | PwD Preferences/Reactions to VR: Post-Session Experience Ratings | Immediately after each session, participants with dementia will be prompted to rate their experience on a visual analog "Star" scale (range of 1 to 5), where 1 indicates the worst possible experience and 5 indicates the best possible experience. | 3 Weeks | |
Other | PwD Preferences/Reactions to VR: Post Session Log | Caregivers will be asked to record any observations and feedback related to their their loved one's reactions to VR (e.g., enjoyment, relaxation, engagement, anxiety/apprehension; what did/did not go well). Caregivers will be asked to make these recordings immediately after intervention sessions. | 3 Weeks | |
Other | PwD Preferences/Reactions to VR: Time Spent in Each VR Medium | This objective metrics of VR usage will be will be unobtrusively collected through the VR&R application for the duration of the study. | 3 Weeks | |
Other | PwD Preferences/Reactions to VR: Head Movements in VR | This objective metrics of VR usage will be will be unobtrusively collected through the VR&R application for the duration of the study. | 3 Weeks | |
Other | PwD Preferences/Reactions to VR: Progression within the Game | This objective metrics of VR usage will be will be unobtrusively collected through the VR&R application for the duration of the study. | 3 Weeks | |
Primary | Change in Caregiver Respite and Burden: Short Zarit Burden Interview | The Short Zarit Burden Interview tool will be completed by caregiver-participants and will be used to evaluate subjective feelings of caregiver burden associated with being a caregiver for the person with dementia. The Short Zarit Burden Interview is a 6-item questionnaire that employs a 5-point Likert scale. Total scores range from 0-24 where higher scores indicate greater feelings of caregiver burden. | 4 Weeks | |
Primary | Change in Caregiver Respite and Burden: Caregiver Phone Interview | The caregiver will be asked to take part in a pre- and post- intervention phone interview (approximately 15 minutes in length, audio-recorded). The interview will include open-ended questions to gather qualitative information on the impact of the VR intervention on the caregiver and PwD (i.e., whether there were any changes to baseline PwD & caregiver well-being/QoL, BPSD, caregiver burden, and caregiver respite following the intervention), as well as feedback on the VR mediums in terms of their ability to promote caregiver respite. | 4 Weeks | |
Primary | Caregiver Respite and Burden: Post-Session Log | Caregivers will be asked to describe their time while the PwD was using VR in a paper-based log. This tool aims to capture if the caregiver was able to obtain additional respite, and the degree to which they were able to obtain respite (i.e., the degree to which caregivers were able to remain vigilant and at the same time detach and focus on their own task). Caregivers will also have the opportunity to record observations of the PwD's reactions to/experience with the VR intervention, as well as additional feedback and reflections of their own or from discussion with the PwD. | 3 Weeks | |
Secondary | Change in PwD Behavioural and Psychological Symptoms of Dementia: Apathy | A modified version of the Apathy Evaluation Scale (AES) will be completed by the caregiver to measure symptoms related to apathy. | 4 Weeks | |
Secondary | Change in PwD Behavioural and Psychological Symptoms of Dementia: Depression | The Short Geriatric Depression Scale (GDS) and will be completed by participants with dementia. The GDS is a 15-item questionnaire employing "yes/no" response options that has been validated for use with individuals with mild to moderate cognitive impairment. | 4 Weeks | |
Secondary | Change in PwD Behavioural and Psychological Symptoms of Dementia: Neuropsychiatric Symptoms | The Neuropsychiatric Inventory-Questionnaire (NPI-Q) will be completed by the caregiver. The NPI-Q is a 12-item questionnaire that measures neuropsychiatric symptoms (e.g., related to related to mood, behavioural disturbance) as well as caregiver distress corresponding to reported symptoms. | 4 Weeks | |
Secondary | Change in PwD and Caregiver Quality of Life | Quality of Life in Alzheimer's Dementia (QoL-AD) will be administered to participants with dementia and caregiver-participants to evaluate subjective quality of life. The QoL-AD is a 13-item questionnaire employing 4-point Likert scales. Calculated scores range from 0-52. Higher scores indicate greater subjective quality of life. | 4 Weeks | |
Secondary | Change in PwD and Caregiver Well-Being | WHO-5 Well-Being Index will be administered to participants with dementia and caregiver-participants to evaluate subjective wellbeing. The WHO (Five) is a 5-item questionnaire employing 6-point Likert scales. Calculated scores range from 0-25. A score of 0 represents the worst possible and a score of 25 represents the best possible quality of life. A score below 13 represents poor wellbeing. A change of 10% represents a significant change in wellbeing. | 4 Weeks | |
Secondary | Immediate Impact of Intervention on PwD Mood | Participants with dementia will be prompted to select from a set of eight faces displaying different emotions, immediately before and after each VR-therapy session. These include positive emotions (happy, joyful, relaxed) and negative emotions (anxious, sad, angry, confused, indifferent). These metrics will be collected before and after each intervention session (i.e., at a time-interval of approximately 30 minutes, depending on session length.) | 3 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05686486 -
Gentle Gymnastics and Relationship Between Family Caregivers and Residents With Dementia in Nursing Homes
|
N/A | |
Terminated |
NCT05451693 -
Outreach-ER: A Dementia Care Intervention Program
|
||
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Enrolling by invitation |
NCT06040294 -
Dementia and Disability Simulation for College Nursing Students' Senior Activity Facilitation Skills
|
N/A | |
Completed |
NCT05114187 -
An Internet-Based Education Program for Care Partners of People Living With Dementia
|
N/A | |
Recruiting |
NCT06322121 -
Vascular Aspects in Dementia: Part 2
|
||
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT04426838 -
Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad
|
N/A | |
Recruiting |
NCT03462485 -
Pilot Study of the Effects of Playing Golf on People With Dementia
|
N/A | |
Active, not recruiting |
NCT03677284 -
Managing Time With Dementia: Effects of Time Assistive Products in People With Dementia
|
N/A | |
Completed |
NCT03849937 -
Changing Talk Online (CHATO) Study
|
N/A | |
Recruiting |
NCT06284213 -
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
|
||
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Completed |
NCT04571697 -
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Recruiting |
NCT06033066 -
Financial Incentives and Recruitment to the APT Webstudy
|
N/A | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT05684783 -
Dementia Champions in Homecare
|
||
Completed |
NCT03147222 -
Function Focused Care: Fracture Care at Home
|
N/A |